New Horizon Health Ltd. was a Hong Kong-based cancer screening company that developed non-invasive early detection tests for colorectal cancer and other malignancies. Founded in 2015, it went public on the Hong Kong Stock Exchange (stock code 6606) and was valued at nearly HK$40 billion (US$5.1 billion) at its peak, making it one of the most hyped biotech listings in Hong Kong.
The company's shares were suspended on March 28, 2024, after the exchange raised concerns about its ability to meet trading requirements. A winding-up petition was filed, and the Cayman Court appointed provisional liquidators on July 8, 2025. The company failed to meet the conditions for resuming trading by the September 27, 2025 deadline.
On October 10, 2025, the HKEX listing committee formalised the delisting, and the company's shares were cancelled on October 27, 2025. Fraud claims were cited in the delisting process, and the company's collapse wiped out billions in market value. The case became a cautionary tale about the risks of investing in high-growth biotech companies with unproven business models.
The HK$40B market value was wiped out when the company failed to meet resumption conditions, leading to liquidation and delisting.
The company failed to meet HKEX resumption conditions after an 18-month trading suspension, indicating deep structural problems in its business and governance.
Fraud allegations eroded investor confidence and made it impossible to raise the capital needed to continue operations or restructure.
The cancer screening market was crowded with competitors, and New Horizon's tests faced questions about clinical accuracy and commercial viability.
As a biotech company with no profitable track record, it had no revenue buffer to absorb the cost of legal proceedings, liquidator fees, and the reputational damage from fraud claims.
A biotech with a hyped IPO and no profits is one bad quarter from a death spiral. Once trading is suspended and fraud is alleged, there is no recovery — the liquidity crisis becomes a solvency crisis.
New Horizon Health was delisted from the Hong Kong Stock Exchange on October 27, 2025. Provisional liquidators were appointed by the Cayman Court. The company's collapse was covered by financial media including Caixin and Reuters as a warning about the risks of biotech stock speculation in Hong Kong.
FOLLOW THE EVIDENCE